AXIM OTC
AXIM Biotechnologies, Inc.
1W: -6.1%
1M: -7.6%
3M: -19.1%
YTD: -70.4%
1Y: -38.2%
3Y: -85.2%
5Y: -99.4%
$0.00
-0.00 (-2.86%)
Weekly Expected Move ±16.2%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$70K
+78.3% ▲
5Y CAGR: -38.5%
Gross Profit
-$369K
-1034.4% ▼
Operating Income
-$2M
+35.9% ▲
Net Income
-$4M
+56.4% ▲
EPS (Diluted)
$-0.01
+68.9% ▲
EBITDA
-$2M
+62.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $60K | $9K | $40K | $70K |
| YoY Growth | -100.0% | +0.0% | -85.3% | +345.3% | +78.3% |
| Cost of Revenue | $16K | $0 | $426K | $0 | $440K |
| Gross Profit | -$16K | $60K | -$417K | $40K | -$369K |
| Gross Margin | — | 100.0% | -4701.4% | 100.0% | -524.1% |
| R&D Expenses | $427K | $285K | $154K | $125K | $40K |
| SG&A Expenses | $5M | $6M | $4M | $2M | $1M |
| Operating Expenses | $5M | $8M | $5M | $3M | $1M |
| Operating Income | -$5M | -$8M | -$5M | -$3M | -$2M |
| Operating Margin | — | -13207.1% | -52425.6% | -6961.0% | -2502.3% |
| Interest Expense | $321K | $743K | $2M | $1M | $636K |
| Income Before Tax | -$6M | -$16M | -$6M | -$8M | -$4M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$7M | -$17M | -$6M | -$8M | -$4M |
| Net Margin | — | -27320.8% | -67120.7% | -20395.0% | -4985.2% |
| EPS (Diluted) | $-0.06 | $-0.13 | $-0.04 | $-0.04 | $-0.01 |
| EBITDA | -$5M | -$13M | -$4M | -$6M | -$2M |
| Shares Outstanding | 110M | 132M | 165M | 228M | 319M |